G1 Therapeutics, the US healthcare company focused on cancer treatments, has appointed experienced IRO William Roberts as its new vice president of investor relations and corporate communications.
Roberts joins from Zynerba Pharmaceuticals where he served as vice president of IR and corporate communications for nearly four years. Prior to that, he was vice president of IR at Adaptimmune.
Earlier in his career, Roberts worked as vice president of IR and communications at ViroPharma for 10 years. During this time, ViroPharma won best overall IR (small cap) at the IR Magazine Awards – US 2013. Roberts also jointly won best IR officer (small cap) at the same event.
‘I am excited to join G1 Therapeutics and be part of an organization that is dedicated to improving the lives and outcomes of people living with cancer,’ Roberts tells IR Magazine.
‘[This year] is an exciting one for G1 as we prepare to launch our first product, trilaciclib. With this milestone on the horizon, my priority is to engage a variety of stakeholders, including the investment community, to broadly raise awareness about trilaciclib and our mission to fundamentally change the patient chemotherapy experience.’
